Get the Stockscreener App
1.07
2.73%
-0.03
After Hours:
1.07
Fate Therapeutics Inc stock is traded at $1.07, with a volume of 767.00K.
It is down -2.73% in the last 24 hours and down -6.14% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
767.00K
Relative Volume:
0.44
Market Cap:
$122.63M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.6485
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-13.71%
1M Performance:
-6.14%
6M Performance:
-17.69%
1Y Performance:
-78.07%
1-Day Range:
$1.06
$1.11
1-Week Range:
$1.06
$1.3495
52-Week Range:
$0.6611
$4.655
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.07 | 126.10M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - jammulinksnews.com
What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
What makes Fate Therapeutics Inc. stock price move sharplyMaximize your gains with professional insights - jammulinksnews.com
How does Fate Therapeutics Inc. generate profit in a changing economyFree Stock Market Trend Analysis - jammulinksnews.com
What is Fate Therapeutics Inc. company’s growth strategyUnlock exclusive stock market insights - jammulinksnews.com
What are Fate Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals and alerts - jammulinksnews.com
How does Fate Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for risk mitigation - jammulinksnews.com
Does Fate Therapeutics Inc. stock perform well during market downturnsMassive stock growth - jammulinksnews.com
Is Fate Therapeutics Inc. a growth stock or a value stockInvest confidently with market-leading analysis - jammulinksnews.com
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases - TipRanks
How volatile is Fate Therapeutics Inc. stock compared to the marketTop Growth Tracker With Low Risk - jammulinksnews.com
Published on: 2025-07-30 19:50:13 - metal.it
Published on: 2025-07-30 17:10:31 - beatles.ru
Published on: 2025-07-30 08:12:45 - metal.it
How Resilient Is Fate Therapeutics Inc. Stock During Economic DownturnsDaily Smart Money Movement Monitor Activated - metal.it
Why Fate Therapeutics Inc. stock attracts strong analyst attentionStock Market Watch With Alerts Shows Unusual Activity - beatles.ru
Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalSector Based Breakout Stock Forecast Issued - metal.it
Ranking Fate Therapeutics Inc. among high performing stocks via toolsWeekly Gain Forecast with Momentum Indicators - Newser
Can Fate Therapeutics Inc. stock recover from recent declineLong Term Safe Yield Focus - metal.it
What institutional investors are buying Fate Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
Is Fate Therapeutics Inc. stock overvalued or undervaluedAchieve fast wealth growth with smart picks - jammulinksnews.com
What are analysts’ price targets for Fate Therapeutics Inc. in the next 12 monthsDiscover stocks with massive upside potential - jammulinksnews.com
Will Fate Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsDaily Top Gainers - metal.it
Has Fate Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Investment Group - Newser
What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional
How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):